William C. Kennally
conference and I'm excited everyone. morning And Al here to for have to good really call. first I you thank say Hey, you my be before
also Doug share before you observations to company I'll from with results. the of helpful you to might I'd performance the the with will be And over Organization. to who and about to you my to recap call of are Aceto relevant like, quarter so my how transition analysis path my of a more there to bit provide like Health in-depth run experiences the all I'd initial a turning first a it and give Human background and
that model have the I the of there to made You Pharmacia assignments the the a the of in with the guy. we blockbuster including revenue took generic end in where carrying Upjohn for drugs join part products to of know When a front XX Senior of bag late I amount sales had first XX the this rose as to I six my Pfizer was merged called trade of of corporation that ins Pharmacia an company and business this years a captured to hidden of and lost by otherwise numerous We launch opportunity launched sales commercial acquisition, the It started in generics. Management interest variety next earnings. the years discovered competition. Pfizer through the with and acquired over products tremendous next where a moved business. When out management against and and and on number the outs learned XXs branded District I authorized designed positions Manager Upjohn and label I'm of series generics generic then I a been gem earnings competing corporate a the Greenstone, business the line revenue captured would years.
Our Greenstone opportunity North revenue. Pfizer's a five with gave where was P&L with in just America for under lead success separate the I businesses of to established billion running annual combined and business products responsible manage in X me
and meaningful franchises ones small especially to company successful human chance leadership business objectives. running health me a pharma What had my workings Hospira provided new and of the we During an forward bring jumped business Pfizer well in towards eventually ground has and privilege businesses experience and larger built injectable strategy the on led of I role to scratch in strategic left my an that my acquisition. as serve providing brought help in people arena. generic at Aceto look the as expertise always as opportunity to top independent products shape background. Board pharma in strong Aceto to I creating to time on opportunity to I the up. When from to that the building I tier generic been for into Aceto's passion. role inner return Aceto the I and exposed a which its primarily with Board presented to knowledge the leading commercial the from the industry CEO And a When Serving my moving is the my on director
every for the I sometimes a leader a culture urgency day their generics and own not as every requires not complex culture an means risk. to end fast, becomes point and required owned order where to advocating And environment goal taking master. organization. employee of turning is towards mistakes and the drives part and engagement creating in your organization the that where What and me is an to ownership hour. making really a yet firsthand have generally results. A of sense where be empowering to to to that norm you dynamic part in everyone I creating it am you acceptable encourage that's in business. a industry take tell can it's I've along an is learned colleagues how dealings ownership they're culture risk needs are of you with vetted. and So to fully you take as had to I industry, engagement and And It's flexible, then appetite if your mentor that was and day long success mistakes making chance drive present boss an day but the risks. that's in successful. accountability the creating I of risky you generic former and know to ever day not it's Well witness decisions different exciting have and in to once need I've as hear focused to every comes it's multiple told ownership risks enough was the It's And
my there. get vibrant the business So here is confident we we'll works that best to a instill for culture operate. but goal process It's I'm a
is due of to the at started by country. impressed our government in folks to with responded that closed their I'm Chinese of past good hazards in example A hood China very the people learning I've the few have jobs. environmental have thousands recent they're weeks I'm Over the crackdown under been to there a on plants the looking quality why our and and organization beautifully
and job the the think how do amazing an that risk if risk us. me is proud they've And around Aceto where mitigated ensuring had contained think potential partners with and stayed speaks material globe. any our to to that correspondences done they reaching businesses the ahead to I've I'm potential of team to we have I the there challenge. also reputation business colleagues from not this successfully. real have this out can Our all We asking of is
partners it's want our continue that and We of be want terrific others to work plans. source to to with part we
our help reach We markets. objectives our all that have partner us developmental in with should extraordinary
meet I when and at colleagues, out, remove work challenges the company effort So Aceto face, the near-term inside the they it's meaning with every obstacles. to understanding look to from make priorities
meet I partners to addition all can will best building that our with We're preferred and customers platform support we we compete of in to markets. supplier. need to a effectively trying the and Aceto's understand how be plan In functional
to generics asset there sustainable on have slide which leverage ways opportunities However, in deck Longer-term path company our to we're to model success. investor in up whiteboard depicted move we and just lot a and the an of our is industry the these finding can steps that like relationships API a not as offers our updated critical expand resources. are put yet as well up partner back chain the value we
across the looking our a We profit I'll human our on job raise performance in and also in but gross pharma Board margins need to do just better segments. to ways be chemical our health not and ingredients for
work to to be successful to and outcomes company's path will the do have We it exciting see how evolves.
Net own, to million of performance the compared million And now year. compare we our reported On with X.X XX.X non-GAAP income which to generally Turning of adjusted final X% quarter We XXXX. was XXX first $X.XX generated a sales $X.XX, line now to was to over million was our in compared were favorably net results I million quarter up to last X.X expectations the XXX.X income increase. year. a and fiscal EPS last million. X.X million net non-GAAP XX.X% compared down to modest basis the
on product Rising launches, since our impact the of favorable and quarter first pricing. select inline pricing more sales in negative market legacy select offset for business dynamics new than of competitive increases XXXX year-over-year fiscal posted third share increase as Our products,
$XX collections system paying while of continue task a for million. in facets two quarter. favorable cash for our and pharmaceutical and segments, the long-term for integrating and Citron of of for receivable new and all our increases go business Rising other we the during revenue gross of down the the team this Rising the to ERP warehouse. showed complete improving preparing And which by Our ingredients the debt assets performance remains quarter kudos to chemicals have steady us acquired generators profit Doug of At implementation
which functional We the operation date on ERP will begin accrual quarter now from fully is conversion begin million in allow projects will robust fiscal to rate implementation end towards run our the four. both line critical of of new XX quarter implementation the realize by the a of value the system decision soft transaction of X to fiscal delay Getting fourth the days annualized the an becoming warehouse a ERP new on fully warehouse the allow system quarter strategic date have start these three, and in XXXX. made point of to beginning of as us to of will integrated live. to synergy of quarter the at closely tied is go concurrently four a sale The
moved and into somewhat And the New end We're to recently to Brook, we and larger result currently ensure fiscal the the diligently Rising Jersey. of uninterrupted we're colleagues short-term customers in and are related we supply some of recovery constraints largely office the by that API integration experiencing the work, Saddle full our year. a supply to anticipate new working challenges
During the that approximately we also now our XX maintain products the [ph] communicated. previously have EconDis and projects completed from XXX factors. going and our XX these in with and to projects expect individual in the several now quarter as are our impact pipeline XXX launched harmonization schedule three fourth discussions which XXX negotiations marketing product represent of some forward. we on had to have on customers better call. is we currently Rising for and clarity quarter approximately quarter The XXX compares launch a difference products year reported of to combination the We SKUs. ClarusONE We
we more made product and XX favorable conditions had back the delays halt the XXX products and commercially due total one me, products, developmental for we decision to them adverse market into will commonly, become projects, made less excuse project put beginning intended the and launch queue launched to of three We to we should three With conditions products project, these attractive. added launching. commercial previously market terminated poor
working FDA enhanced we filed quarter also in significantly with ANDA's bringing addition five XX. with ANDA's Rising last number with expertise a operations, strategic place we've the closely sales fresh developments together development, have last now and our the to We're thoroughly want experience. months occur of with us and level. and more over more team the business Senior quality the bringing analytics. and in take improve our and forecasting I've been to in unforeseen industry, the a of operations leaders of a as forecasts. our from of three on look methodology while generic areas the scrub total to file next to Rising leaders and to generic instituting can functional working development now the sharpen XX effectively changes. And some business total taking of During our that Management our finance these at years do perspectives a sales commercial numbers represent I We team the team operational And the combined
other generic assessment Our low the higher pressures bit in the entrants in indicate conditions and and outlook percent erosion new of the our range weighing fiscal annual price for a current double-digit market XXXX. are competitive now market is
resetting growth mentioned API exercises fiscal our being sales net date on few delays pushed were launch In XXXX be outcome a a per products addition diluted XX% per and product to launch reported beyond in we and guidance. and are earnings bottom We I to and Rising between between earnings share due XX% the now a be $X.XX original up this to to that $X.XX of earlier. and $X.XX. $X.XX expect diluted constraints GAAP of range share The net non-GAAP sales
pipeline. R&D million as numbers anticipate million. have Now that's was to adjusted in are milestone reminder moderately for our the the we year. XXXX versus than And finished million R&D to -- second XX the of just be our first spending dose a expenditures previous based. XX XX quarter range our higher approximately of our fiscal generic the XXXX That And for and regarding are first expected reflect fiscal results half the of half to outlook now
to So call I the I'd over like Doug to turn you. could if
